$RPTX
Repare Therapeutics Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022007897 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $408.0K $170.0K
YoY Change 140.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.779M $5.240M
YoY Change 67.54% 140.37%
% of Gross Profit
Research & Development $26.46M $16.51M
YoY Change 60.26% 91.3%
% of Gross Profit
Depreciation & Amortization $516.0K $322.0K
YoY Change 60.25% 64.29%
% of Gross Profit
Operating Expenses $35.24M $21.75M
YoY Change 62.04% 101.07%
Operating Profit -$34.83M -$21.58M
YoY Change 61.39% 99.54%
Interest Expense $112.0K $30.00K
YoY Change 273.33% -101.73%
% of Operating Profit
Other Income/Expense, Net $104.0K $26.00K
YoY Change 300.0% -101.5%
Pretax Income -$34.73M -$21.55M
YoY Change 61.11% 71.77%
Income Tax $32.00K -$137.0K
% Of Pretax Income
Net Earnings -$34.76M -$21.42M
YoY Change 62.29% 69.96%
Net Earnings / Revenue -8518.87% -12598.24%
Basic Earnings Per Share -$0.83
Diluted Earnings Per Share -$830.3K -$580.2K
COMMON SHARES
Basic Shares Outstanding 41.87M 36.90M
Diluted Shares Outstanding 41.86M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $305.1M $311.4M
YoY Change -2.01% 272.04%
Cash & Equivalents $305.1M $311.6M
Short-Term Investments $6.528M $7.500M
Other Short-Term Assets $3.915M $3.900M
YoY Change 0.38% 387.5%
Inventory
Prepaid Expenses $3.915M
Receivables
Other Receivables
Total Short-Term Assets $319.2M $328.2M
YoY Change -2.73% 273.38%
LONG-TERM ASSETS
Property, Plant & Equipment $5.397M $8.800M
YoY Change -38.67% 183.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $586.0K $2.100M
YoY Change -72.1% -19.23%
Total Long-Term Assets $17.92M $10.90M
YoY Change 64.41% 91.23%
TOTAL ASSETS
Total Short-Term Assets $319.2M $328.2M
Total Long-Term Assets $17.92M $10.90M
Total Assets $337.1M $339.1M
YoY Change -0.58% 262.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.546M $3.400M
YoY Change -54.53% 3.03%
Accrued Expenses $18.47M $6.500M
YoY Change 184.08% 364.29%
Deferred Revenue $11.87M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $34.08M $12.40M
YoY Change 174.86% 69.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $44.41M $59.00M
YoY Change -24.74% 602.38%
Total Long-Term Liabilities $44.41M $59.00M
YoY Change -24.74% 602.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.08M $12.40M
Total Long-Term Liabilities $44.41M $59.00M
Total Liabilities $78.49M $71.40M
YoY Change 9.93% 354.78%
SHAREHOLDERS EQUITY
Retained Earnings -$245.0M
YoY Change
Common Stock $503.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $258.7M $267.7M
YoY Change
Total Liabilities & Shareholders Equity $337.1M $339.1M
YoY Change -0.58% 262.29%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$34.76M -$21.42M
YoY Change 62.29% 69.96%
Depreciation, Depletion And Amortization $516.0K $322.0K
YoY Change 60.25% 64.29%
Cash From Operating Activities -$30.01M -$14.23M
YoY Change 110.91% 46.41%
INVESTING ACTIVITIES
Capital Expenditures $487.0K $772.0K
YoY Change -36.92% 2473.33%
Acquisitions
YoY Change
Other Investing Activities $890.0K
YoY Change
Cash From Investing Activities $403.0K -$772.0K
YoY Change -152.2% 2473.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 241.0K 183.0K
YoY Change 31.69% -17.57%
NET CHANGE
Cash From Operating Activities -30.01M -14.23M
Cash From Investing Activities 403.0K -772.0K
Cash From Financing Activities 241.0K 183.0K
Net Change In Cash -29.29M -14.78M
YoY Change 98.15% 33.15%
FREE CASH FLOW
Cash From Operating Activities -$30.01M -$14.23M
Capital Expenditures $487.0K $772.0K
Free Cash Flow -$30.49M -$15.00M
YoY Change 103.3% 53.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41894235
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
305136000
CY2021 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001808158
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39335
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
CY2022Q1 dei Entity Address Country
EntityAddressCountry
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
CY2022Q1 dei City Area Code
CityAreaCode
857
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
412-7018
CY2022Q1 dei Security12b Title
Security12bTitle
Common shares, no par value
CY2022Q1 dei Trading Symbol
TradingSymbol
RPTX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
334427000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
6528000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
7439000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11921000
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1870000
CY2022Q1 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2986000
CY2021Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
2580000
CY2022Q1 us-gaap Other Receivables
OtherReceivables
663000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
654000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3915000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6314000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
319228000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
351414000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5397000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5604000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7003000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7491000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
586000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
586000
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4935000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3620000
CY2022Q1 us-gaap Assets
Assets
337149000
CY2021Q4 us-gaap Assets
Assets
368715000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1546000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2302000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16936000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18622000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1857000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1721000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11874000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
523000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
34083000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35089000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5154000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5592000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39252000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
39613000
CY2022Q1 us-gaap Liabilities
Liabilities
78489000
CY2021Q4 us-gaap Liabilities
Liabilities
80294000
CY2022Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2021Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41879204
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41879204
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41850162
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41850162
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
481048000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
480699000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
22635000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17988000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245023000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-210266000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
337149000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
368715000
CY2022Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
408000
CY2021Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
166000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26458000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16509000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8779000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5237000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
35237000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
21746000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34829000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21580000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-17000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-31000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
129000
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
64000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34725000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21554000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-137000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2021Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-21417000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34757000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21417000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41861613
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36916734
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
286830000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2057000
CY2021Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-21417000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
267653000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4755000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-34757000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-21417000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4755000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2057000
CY2022Q1 us-gaap Depreciation
Depreciation
516000
CY2021Q1 us-gaap Depreciation
Depreciation
322000
CY2022Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
544000
CY2021Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
371000
CY2022Q1 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
40000
CY2021Q1 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
41000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-21000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-29000
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1315000
CY2021Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
174000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2399000
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2796000
CY2022Q1 rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
399000
CY2021Q1 rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
238000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5000
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1017000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-772000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1201000
CY2022Q1 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1487000
CY2021Q1 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
253000
CY2022Q1 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
153000
CY2021Q1 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-135000
CY2022Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
1347000
CY2021Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
12000
CY2022Q1 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-558000
CY2021Q1 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-114000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-408000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-166000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30006000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14227000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
772000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2650000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1760000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
403000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-772000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
183000
CY2022Q1 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
213000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
241000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
183000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29291000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14782000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
326396000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
305136000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
311614000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
305136000
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
311399000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
215000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
305136000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
311614000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1541000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
286000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2022Q1 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9984000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9984000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9974000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
9974000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2068000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4867000
CY2022Q1 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
11784000
CY2021Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
11272000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1236000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
387000
CY2022Q1 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
1520000
CY2021Q4 rptx Accrued Property And Equipment Purchases
AccruedPropertyAndEquipmentPurchases
1719000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
328000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
377000
CY2022Q1 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
16936000
CY2021Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
18622000
CY2022Q1 rptx Number Of Operating Leases
NumberOfOperatingLeases
4
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
615000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
419000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
67000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
56000
CY2022Q1 us-gaap Lease Cost
LeaseCost
690000
CY2021Q1 us-gaap Lease Cost
LeaseCost
478000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
475000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
299000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M28D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.050
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5322591
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.76
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2233467
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.61
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12235
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.34
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
68953
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
18.98
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7474870
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.00
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
12235
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.34
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000.00
CY2022Q1 rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
20000.00
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0173
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0067
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7847
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7541
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4755000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2057000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4755000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2057000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
53100000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34757000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21417000
CY2022Q1 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-34757000
CY2021Q1 rptx Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-21417000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41861613
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36916734
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58

Files In Submission

Name View Source Status
0000950170-22-007897-index-headers.html Edgar Link pending
0000950170-22-007897-index.html Edgar Link pending
0000950170-22-007897.txt Edgar Link pending
0000950170-22-007897-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20220331.htm Edgar Link pending
rptx-20220331.xsd Edgar Link pending
rptx-20220331_cal.xml Edgar Link unprocessable
rptx-20220331_def.xml Edgar Link unprocessable
rptx-20220331_htm.xml Edgar Link completed
rptx-20220331_lab.xml Edgar Link unprocessable
rptx-20220331_pre.xml Edgar Link unprocessable
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending